<DOC>
	<DOCNO>NCT01524874</DOCNO>
	<brief_summary>The importance vitamin D ( VitD ) prevention treatment human health condition gain increased attention recent year . As result , medical provider category screen clinical VitD status frequently , yet become challenged best advise patient regard repletion VitD status , i.e . form VitD replacement effective . It recognize achieve significant effect - serum concentration &gt; 30ng/ml ( 75 nmol/ml ) - necessary , well safe , recommend substantially high dose previously think sufficient . These high dos easily achieve orally . This clinical trial aim compare absorption three available form fat-soluble vitamin , due potential difference absorption different preparation . High-quality powder , chewable lipid-emulsified VitD readily available supplement , yet systematically compare . This three-arm , randomized clinical trial compare difference serum 25-hydroxycholecalciferol ( 25-OH ) D concentration three arm baseline random administration one three VitD preparation 12-weeks dosage 10,000 IU VitD per day . The investigator hypothesize three form vitD result equivalent increase serum 25OHD .</brief_summary>
	<brief_title>Comparative Effectiveness Vitamin D Repletion Strategies</brief_title>
	<detailed_description>VitD numerous hormonal effect , include regulation Ca2+ Mg2+ , well effect numerous gene , include insulin androgen . Mounting literature demonstrate association VitD insufficiency cancer , diabetes heart disease . VitD insufficiency , define concentration serum 25-hydroxycholecalciferol ( 25-OHD ) &lt; 33ng/ml ( 82.5 nmol/ml ) , common latitude ; prevalence estimate ~35 % `` healthy '' population . VitD test replacement gain popularity clinical practice . It know whether difference effect equivalent dos emulsify vs. non-emulsified cholecalciferol ( VitD3 ) supplementation , reflect quantitative change serum 25-OHD . However , clinical observation reveal average 4.4 month , subject take 4000 iu daily emulsify form cholecalciferol improve 25-OHD level 6.76 ng/mL take 5,000 iu daily non-emulsified form . The safety take 10,000 IU/day confirm . Taking dose 12 week cause robust increase serum 25-OHD . This study provide preliminary data compare three high quality VitD3 supplement , one powder capsule , one chewable tablet , lipid-emulsified liquid . Future study compare `` good '' supplement conventional VitD replacement use VitD2 .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Avitaminosis</mesh_term>
	<mesh_term>Rickets</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Provision inform consent Between1865 year age ; agerelated decline absorption , transport liver hydroxylation orallyconsumed VitD ( Harris , 1999 ) therefore adult older 65 exclude . This population also great risk medication potential medication interaction , e.g . anticoagulant . Willingness perform baseline screen test : serum 25OHD , CBC , Comprehensive metabolic chemistry panel ( electrolyte , hepatic renal function test , lipid , HgA1C , insulin glucose ) Screening serum 25OHD &lt; 33ng/ml ( 82.5 nmol/ml ) . If &gt; =33ng/ml ( 82.5 nmol/ml ) , subject participate research study baseline control nested study Klotho TLR4 . Ability read speak English Willingness randomize one three active treatment 3 month Subjects serum baseline 25OHD &gt; =33ng/ml ( 82.5 nmol/ml ) exclude VitD sufficient baseline control recruitment goal meet Subjects historical current use extradietary VitD , multivitamin , previous 3 month . LFTs : AST &gt; 60 U/L ; ALT &gt; 65 U/L ; Alkaline phosphatase &gt; 120 U/L . Total bilirubin &gt; 1.5 mg/dL Serum creatinine &gt; 1.4 mg/dL ; BUN &gt; 25 mg/dL5 . Subjects pregnant , could become pregnant , unless use regular birth control ( OCPs , condom , IUD ) . Subjects establish osteoporosis . Subjects history symptom parathyroid disorder . Subjects difficulty swallow pill . Subjects unwilling use sunscreen . Subjects past adverse reaction sunscreen . Subjects take medication previous 3 month interfere metabolism VitD ( anticonvulsant , anticoagulant , oral corticosteroid , barbiturate ) . Subjects psychological condition substance abuse may make subject non adherent , history bipolar disorder , mania , untreated anxiety mood disorder , determine site PI . Other severe illness mental incapacity , opinion site PI , would render potential subject incapable participating study . Allergy sesame oil base Heart arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>vitamin</keyword>
	<keyword>cholecalciferol</keyword>
	<keyword>nutritional supplement</keyword>
	<keyword>hypovitaminosis</keyword>
	<keyword>klotho</keyword>
	<keyword>toll like receptor 4</keyword>
</DOC>